Extension Study Of Tanezumab In Osteoarthritis

Back to Search
Print
Bookmark Trial

NCT00809783

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pinncale Research Group, LLC
Anniston, Alabama, 36201, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Osteoarthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-99 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Must have participated in previous (specific) Phase 3 trials of Tanezumab in osteoarthritis

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Willing to comply with scheduled visits and treatment plan Is medically fit to
participate in the trial in the judgement of the Investigator

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

OsteoarthritisStudy Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement
NCT00454298
  1. Boston, Massachusetts
  2. Boston, Massachusetts
  3. Newton, Massachusetts
  4. Winchester, Massachusetts
  5. Worcester, Massachusetts
ALL GENDERS
55 Years+
years
MULTIPLE SITES
OsteoarthritisClinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee
NCT01102660
  1. Paramount, California
  2. Spring Valley, California
  3. Valley Village, California
  4. Daytona Beach, Florida
  5. Ormond Beach, Florida
  6. Plantation, Florida
  7. Plantation, Florida
  8. South Miami, Florida
  9. Gurnee, Illinois
  10. Overland Park, Kansas
  11. Overland Park, Kansas
  12. Overland Park, Kansas
  13. Prairie Village, Kansas
  14. Wichita, Kansas
  15. Fall River, Massachusetts
  16. Hyannis, Massachusetts
  17. New Bedford, Massachusetts
  18. St. Louis, Missouri
  19. Rochester, New York
  20. Wilmington, North Carolina
  21. Kettering, Ohio
  22. Pawtucket, Rhode Island
  23. Mt. Pleasant, South Carolina
  24. New Tazewell, Tennessee
  25. Dallas, Texas
  26. San Antonio, Texas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
OsteoarthritisA Study Of The Effect Of CE-224535 On Knee OA (Osteoarthritis) Pain
NCT00418782
  1. Anniston, Alabama
  2. Bayou La Batre, Alabama
  3. Birmingham, Alabama
  4. Birmingham, Alabama
  5. Birmingham, Alabama
  6. Hot Springs, Arkansas
  7. Northridge, California
  8. Sacramento, California
  9. Tarzana, California
  10. Denver, Colorado
  11. Denver, Colorado
  12. Westminster, Colorado
  13. Clearwater, Florida
  14. DeFuniak Springs, Florida
  15. Destin, Florida
  16. Pensacola, Florida
  17. Chicago, Illinois
  18. Gurnee, Illinois
  19. Avon, Indiana
  20. Indianapolis, Indiana
  21. Gretna, Louisiana
  22. Kenner, Louisiana
  23. Metairie, Louisiana
  24. Baltimore, Maryland
  25. Frederick, Maryland
  26. Flowood, Mississippi
  27. Columbia, Missouri
  28. Kansas City, Missouri
  29. Missoula, Montana
  30. Trenton, New Jersey
  31. Beavercreek, Ohio
  32. Cincinnati, Ohio
  33. Kettering, Ohio
  34. Ashland, Oregon
  35. Eugene, Oregon
  36. Duncansville, Pennsylvania
  37. Summerville, South Carolina
  38. Collierville, Tennessee
  39. Knoxville, Tennessee
  40. Memphis, Tennessee
  41. Bryan, Texas
  42. Longview, Texas
  43. San Antonio, Texas
  44. San Antonio, Texas
  45. Arlington, Virginia
  46. Spokane, Washington
ALL GENDERS
18 Years+
years
MULTIPLE SITES
OsteoarthritisMeasuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.
NCT00484718
  1. Palo Alto, California
  2. Stanford, California
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Extension Study Of Tanezumab In Osteoarthritis
Official Title  ICMJE A PHASE 3, MULTICENTER, RANDOMIZED, LONG TERM STUDY OF THE SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
Brief Summary Safety extension study of Phase 3 Osteoarthritis trials with Tanezumab
Detailed Description This study was terminated on 27 October 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Osteoarthritis
Intervention  ICMJE
  • Biological: tanezumab
    Tanezumab 10 mg
    Other Name: RN624
  • Biological: tanezumab
    Tanezumab 5 mg
    Other Name: RN624
  • Biological: tanezumab
    Tanezumab 2.5 mg
    Other Name: RN624
Study Arms  ICMJE
  • Experimental: Tanezumab 10 mg
    Tanezumab 10 mg
    Intervention: Biological: tanezumab
  • Experimental: Tanezumab 5 mg
    Tanezumab 5 mg
    Intervention: Biological: tanezumab
  • Experimental: Tanezumab 2.5 mg
    Tanezumab 2.5 mg
    Intervention: Biological: tanezumab
Publications * Hochberg MC, Tive LA, Abramson SB, Vignon E, Verburg KM, West CR, Smith MD, Hungerford DS. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program. Arthritis Rheumatol. 2016 Feb;68(2):382-91. doi: 10.1002/art.39492.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: July 6, 2011)		2147
Original Estimated Enrollment  ICMJE
 (submitted: December 16, 2008)		2400
Actual Study Completion Date  ICMJE June 23, 2011
Actual Primary Completion Date November 2, 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Must have participated in previous (specific) Phase 3 trials of Tanezumab in osteoarthritis

Exclusion Criteria:

  • Willing to comply with scheduled visits and treatment plan Is medically fit to participate in the trial in the judgement of the Investigator
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 99 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00809783
Other Study ID Numbers  ICMJE A4091016
P3 LONG TERM SAFETY EXTENSION ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date May 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP